Watch video
ORBERA® fills in the gap between the non-surgical weight loss segment and the surgical weight loss segment.
It is also the ideal solution for pre-surgical weight loss, allowing any type of surgery with less risks.
The comprehensive program combining the use of an intragastric balloon with an individually tailored support program of diet, psychological support and exercise are all strategies to help patients lose and then keep the weight.
  • Weight loss results achieved can be 3x more with ORBERA than with diet and exercise alone;
  • US Pivotal Study demonstrated a mean excess weight loss (EWL) of 38.4% at 6 months;
  • Number 1 in global market share for intragastric balloons;
  • Security profile established with over 220,000 placements worldwide;
  • With over 20 years of history helping thousands of people lose weight;
  • Fills the stomach and encourages portion control;
  • Non-surgical procedure (endoscopic);
  • Temporary treatment that teaches healthy habits to help maintain weight even after the balloon is removed.


Throughout the treatment timeline, ORBERA® was well tolerated by most patients. Common side effects include nausea, vomiting, and gastric pain and usually stops within one to two weeks after placement. Doctors report that patients view their ORBERA® in a very positive light as transient side effects have decreased, judging it as “good”, “very good” or “excellent”.

The ORBERA® balloon was originally conceived by a group of international physicians, who identified characteristics of an ideal and effective intragastric balloon in producing weight loss:

Spherical shape

Smooth and soft surface to reduce the possibility of ulcers;

Sterile saline solution

The ideal sterile solution for filling the balloon;

Volume 400 - 700 CC

It can be filled with a volume between 400-700cc;

Radiopaque valve

To provide easy viewing inside the stomach.


Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing more than 600 million people worldwide, as well as other gastrointestinal disorders.

Our device-based therapies are an alternative to invasive surgical procedures, thus reducing potential complications and overall healthcare costs. Apollo products are available around 80 countries.